Pharmadiet, SLU, a Spain subsidiary of OPKO Health, Inc. has received final marketing approval from Spain's health authority (Agencia Española de Medicamentos y Productos Sanitarios) for commercialization of its oral and injectable formulations of citicoline. OPKO expects to begin commercialization in Spain of its citicoline products during the first quarter of 2014.
OPKO expects that the products will be significant contributors to Pharmadiet's sales and earnings.
Sales of the other citicoline product presently available in Spain, Somazina, exceeded $80 million in 2012. Citicoline also enjoys strong sales throughout Latin America, including those countries where OPKO maintains a growing presence.
Citicoline products are indicated for the treatment of memory disorders and behaviour related to stroke, head injury, chronic disease, as well as degenerative brain disorders. Citicoline enhances the level of phosphatidylcholine in the brain.
OPKO Health, Inc. is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.